BlueCrest Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

BlueCrest Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,542	Closed	-$1.43M	–	270
2023 Q4	$1.35M	Sell	2,542 -326	-11%	-$158K	0.05%	161
2023 Q3	$1.45M	Buy	+2,868	New	+$1.53M	0.06%	158
2022 Q1	–	Sell	-650	Closed	-$434K	–	351
2021 Q4	$434K	Buy	+650	New	+$406K	0.01%	255
2019 Q4	–	Sell	-3,011	Closed	-$877K	–	583
2019 Q3	$877K	Buy	+3,011	New	+$862K	0.06%	205
2017 Q1	–	Sell	-7,866	Closed	-$1.11M	–	955
2016 Q4	$1.11M	Buy	7,866 +4,198	+114%	+$619K	0.06%	348
2016 Q3	$583K	Sell	3,668 -904	-20%	-$139K	0.02%	478
2016 Q2	$676K	Buy	+4,572	New	+$675K	0.03%	443
2016 Q1	–	Sell	-6,667	Closed	-$946K	–	1096
2015 Q4	$946K	Buy	+6,667	New	+$889K	0.04%	423
2015 Q3	–	Sell	-2,372	Closed	-$308K	–	1045
2015 Q2	$308K	Sell	2,372 -533	-18%	-$69.5K	0.01%	705
2015 Q1	$390K	Buy	+2,905	New	+$374K	0.02%	491

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlueCrest Capital Management's TMO Position: Q1 2024 in Review

BlueCrest Capital Management sold out of Thermo Fisher Scientific (TMO) in Q1 2024, closing a stake of 2,542 shares — an estimated $1.43M sold.

BlueCrest Capital Management first reported a position in TMO in Q1 2015 and held it in 10 quarters. The position peaked at $1.45M in Q3 2023. 2,527 funds tracked by Wall St. Rank hold TMO as of Q1 2024.

BlueCrest Capital Management reported no remaining Thermo Fisher Scientific position as of Q1 2024 after selling out during the quarter.
BlueCrest Capital Management sold 2,542 Thermo Fisher Scientific shares in Q1 2024, an estimated $1.43M.
BlueCrest Capital Management first reported a position in Thermo Fisher Scientific in Q1 2015 and held it in 10 quarters.
BlueCrest Capital Management's Thermo Fisher Scientific position peaked at $1.45M in Q3 2023.
2,527 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2024.

Based on BlueCrest Capital Management's 13F filing for Q1 2024, filed 15 May 2024.